Quoin Pharmaceuticals, Ltd. (QNRX)
$4.72
-0.06 (-1.26%)
Rating:
Recommendation:
-
| Symbol | QNRX |
|---|---|
| Price | $4.72 |
| Beta | 0.000 |
| Volume Avg. | 1.51M |
| Market Cap | 6.778M |
| Shares () | - |
| 52 Week Range | 3.58-444.0 |
| 1y Target Est | - |
| DCF Unlevered | QNRX DCF -> | |
|---|---|---|
| DCF Levered | QNRX LDCF -> | |
| ROE | 82.57% | Strong Buy |
| ROA | -348.28% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -111.34% | Sell |
| P/E | - | |
| P/B | -0.20 | Neutral |
Latest QNRX news
About
Download (Excel)Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome. The company also offers three other pipeline products in development, which are also targeting rare skin diseases, including epidermolysis bullosa, Netherton Syndrome, and Scleroderma. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia.